OKUR
OnKure Therapeutics, Inc.
Healthcare — Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Strong Buy
1.3 / 5
4 analysts
$2.54
$-0.18 (-6.79%)
Target:
$19.50
(667.7%)
Price History
52-Week Range
Sign in to add OKUR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $154.31M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.79 |
| EPS (TTM) | $-4.32 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -42.73% |
| Debt/Equity | 0.22 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $19.50 |
| Analysts | 4 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 38.0 |
| Beta | - |
| SMA 20 | $4.19 |
| SMA 40 | $4.26 |
| 52-Week High | $5.38 |
| 52-Week Low | $1.91 |
| 50-Day Avg | $4.23 |
| 200-Day Avg | $3.56 |
| Avg Volume | 299.7K |
| Volume | 239.2K |
Performance Analysis
NEUTRALOKUR presents a mixed picture with both positive and negative indicators.
~
Trading at 18% of its 52-week range.
~
RSI at 38.0 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 4 analysts.
+
Average analyst target of $19.50 implies 667.7% upside.
Recent News
Loading news...
Last updated: Aug 01, 2026 04:17 UTC
Back to Screener Export Report